Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
What is Lexicon Pharmaceuticals's quote symbol?
What is the 52 week high and low for Lexicon Pharmaceuticals (NASDAQ: LXRX)?
How much is Lexicon Pharmaceuticals stock worth today?
How much is Lexicon Pharmaceuticals's stock price per share?
What is Lexicon Pharmaceuticals's Market Cap?